MARKER Clinical trial Colorectal cancer Colibactin and lipids Cancer MICROBIOTA Endoscopic treatment Immune cells Genes Gènes COLON-CANCER Stricture Anti-TNF Immunosuppressant Dysbiose IL23 Disease progression Inflammatory bowel disease IL12 MORTALITY Small molecules Surgery MALT Disability T1118 translocation Dysbiosis Méthylation Tuberculosis IBD Tailored therapy Kidney diseases Survival Colon cancer Safety Anti-TNF agents Methylation Inflammatory Bowel Diseases Ulcerative colitis Disease Progression Cost effectiveness Venous thromboembolism Screening Rituximab Monitoring Gene methylation Resistance Neoadjuvant chemotherapy Crohn’s disease Contraindication Epigenetics Bactéries Patients experience PCR Eligibility Colonic epithelial primary cells Fecal microbiota Inflammatory bowel diseases Therapeutics Vedolizumab Colorectal cancer Parvimonas micra Thérapie ciblée Consensus CARCINOGENESIS Inhibitor Microbiota HIV Colon Alkylating agents Cell adhesion Patient-reported outcome Drug Bacteria Inclusion Acceptability Intestinal crypts 18 FDG-PET/CT Rituximab plus chlorambucil Biomarker Résistance Biologics DNA METHYLATION Epigénétiques Helicobacter pylori Colectomy Clinical guidelines Microbiote Heart disease risk factors Maintenance therapy Effectiveness Gene expression DNA methylation Over 80s Original Article Clinical Algorithm Upper gastrointestinal tract RISK Eradication Ustekinumab Primary sclerosing cholangitis Crohn's disease